Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3-year follow-up of prior TMC435-treated hepatitis C subjects
2010-019843-20Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of simeprevir in hepatitis C virus infection, sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of patients with undetectable HCV RNA. Started Aug 2010; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-019843-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019843-20.